NAC provides the raw material for glutathione synthesis, supporting Phase II detoxification
Fragment B is selected from the group consisting of fragment B Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(X2)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-resin, referred to as fragment B ( 12-31) or SEQ ID No 9, fragment B 13-31) or SEQ ID No 10 fragment B 8-31) or SEQ ID No 11, and fragment B 6-31 or SEQ ID No 12, wherein X2 is N-( l-oxohexadecyl)-L-y-glutamyl (Pal-Glu) for liraglutide, and X2 is N-( 17-carboxy-l-oxoheptadecyl)-L-y-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-2-[2- (2-aminoethoxy)ethoxy]acetyl for semaglutide, optionally protected
Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg J, Chen Z (2017) Modeling physiological events in 2D vs
The critical need for new medication is highlighted by the rise in antimicrobial resistance